1. Dipòsit Digital de la Universitat de Barcelona
  2. Recerca
  3. Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)
  4. Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/206262
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFontanals Martínez, Sandra-
dc.contributor.authorEsteve, Anna-
dc.contributor.authorGonzález, Andrea-
dc.contributor.authorIbáñez, Cristina-
dc.contributor.authorMesía Nin, Ricard-
dc.contributor.authorClopés Estela, Ana-
dc.date.accessioned2024-01-24T12:00:45Z-
dc.date.available2024-01-24T12:00:45Z-
dc.date.issued2024-01-09-
dc.identifier.issn2052-1707-
dc.identifier.urihttp://hdl.handle.net/2445/206262-
dc.description.abstractOff-label use (OLU) is quite common in oncology due to the complexity of cancer and the time-consuming regulatory process. However, outcomes of OLU in cancer treatment remain unclear. This study aimed to evaluate the overall survival (OS), event-free survival (EFS), duration of treatment (DOT), and reason for treatment discontinuation in patients receiving immune checkpoint inhibitors (ICI) as OLU for solid tumors from 2011 to 2020. The study collected data on 356 episodes (353 patients), with a median age of 64.4 years, 36.2% women, and 14.6% ECOG >= 2. Median OS was 15.7 (11.9-18.7) months, and median EFS was 5.4 (3.8-6.6) months. Men, patients with metastatic disease or ECOG-PS higher than 1, had worse survival outcomes. The findings derived from this study provide valuable information regarding the real-world use of ICI-OLU and contributes to enhancing the decision-making process for individuals with cancer. Further research on immunotherapy outcomes of OLU in cancer is needed. image-
dc.format.extent7 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherWiley-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1002/prp2.1167-
dc.relation.ispartofPharmacology Research & Perspectives, 2024, vol. 12, num. 1-
dc.relation.urihttps://doi.org/10.1002/prp2.1167-
dc.rightscc by-nc-nd (c) Fontanals, Sandra et al., 2023-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationOncologia-
dc.subject.classificationImmunoteràpia-
dc.subject.otherOncology-
dc.subject.otherImmunotheraphy-
dc.titleReal‐world treatment outcomes of immune checkpoint inhibitors used off‐label in oncology: A comprehensive cancer institution experience-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2024-01-24T08:27:08Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid38193611-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
Pharmacology Res Perspec - 2024 - Fontanals - Real‐world treatment outcomes of immune checkpoint inhibitors used.pdf1.89 MBAdobe PDFView/Open
Show simple item record


This item is licensed under a Creative Commons License Creative Commons